SCHEMBL5638525

SCHEMBL5638525

O=C(O)N[C@H]1CCCCN(C(=O)c2ccccc2)C1=O

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ GAA P10253 1/20 0.50
▸ TP53 P04637 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ EPHX2 P34913 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ EPHX1 P07099 1/20 0.43
▸ L3MBTL3 Q96JM7 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MME P08473 1/20 0.41
▸ ACE P12821 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ SLC18A3 Q16572 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637467 0.84 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2GAATP53TSHR
SCHEMBL5637461 0.84 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2GAATP53TSHR
SCHEMBL5637813 0.81 RAB9A (0.48) ALDH1A1SMN1; SMN2GAATP53TSHR
SCHEMBL5640381 0.80 ALDH1A1 (0.50) ALDH1A1EPHX2HPGDL3MBTL1MME
SCHEMBL5638260 0.78 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2GAATP53TSHR
SCHEMBL8778504 0.78 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2GAATP53TSHR
SCHEMBL5638919 0.78 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MMEACE
SCHEMBL5638966 0.78 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2EPHX2EPHX1MME
SCHEMBL5639244 0.77 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2GAATSHRMME
SCHEMBL5637475 0.77 KDM4E (0.51) ALDH1A1SMN1; SMN2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 — — EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 ALDH1A1 1286/4885SMN1; SMN2 4121/4885GAA 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback